Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 12/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8655784 | 0.84 | HPGD (0.51) | GRM1XDHPI4KAPI4K2BPI4K2A | |
| SCHEMBL5432320 | 0.82 | GRM1 (0.46) | GRM1XDHPI4KAPI4K2BPI4K2A | |
| SCHEMBL5438914 | 0.82 | TSHR (0.49) | GRM1RAB9AXDHGRM5LMNA | |
| SCHEMBL5428705 | 0.81 | RAB9A (0.46) | GRM1RAB9AXDHPI4KAPI4K2B | |
| SCHEMBL5429563 | 0.81 | RAB9A (0.46) | GRM1RAB9AXDHPI4KAPI4K2B | |
| SCHEMBL5429766 | 0.79 | GRM1 (0.51) | GRM1XDHGRM5MAPK1 | |
| SCHEMBL5438383 | 0.77 | RAB9A (0.45) | GRM1RAB9AXDHPI4KAPI4K2B | |
| SCHEMBL1997653 | 0.77 | CDK1 (0.41) | GRM1XDHGRM5 | |
| SCHEMBL13320628 | 0.74 | PI4KA (0.51) | GRM1XDHPI4KAPI4K2BPI4K2A | |
| SCHEMBL5432008 | 0.74 | RAB9A (0.42) | GRM1RAB9AXDHPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | GRM1 136/4885RAB9A 2806/4885XDH 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.